Is meropenem active against Escherichia coli and Enterobacter cloacae?

Meropenem Coverage for E. coli and Enterobacter cloacae

Yes, meropenem has excellent activity against both Escherichia coli and Enterobacter cloacae when these organisms are susceptible (non-carbapenem-resistant). According to the FDA label, meropenem is specifically indicated for infections caused by E. coli and demonstrates in vitro activity against Enterobacter cloacae 1.

Spectrum of Activity

E. coli Coverage

• Meropenem is FDA-approved for E. coli infections, including complicated skin and skin structure infections and complicated intra-abdominal infections 1
• The drug binds to penicillin-binding proteins (PBPs) 2,3, and 4 of E. coli, achieving bactericidal activity 1
• Clinical studies confirm potent and stable antibacterial activity against E. coli blood isolates 2

Enterobacter cloacae Coverage

• E. cloacae is listed in the FDA label as having in vitro susceptibility to meropenem, with at least 90% of isolates exhibiting MIC values ≤ susceptible breakpoint 1
• However, the FDA notes that "efficacy of meropenem in treating clinical infections caused by these bacteria have not been established in adequate and well-controlled clinical trials" 1
• Research demonstrates meropenem activity against E. cloacae in various infection models 3, 4

Critical Caveats and Resistance Considerations

Carbapenem Resistance

The major limitation is carbapenem resistance. Meropenem will NOT be effective against:

• Carbapenem-resistant Enterobacterales (CRE) producing carbapenemases (KPC, NDM, IMP types) 5, 6
• E. cloacae strains producing carbapenem-hydrolyzing β-lactamases like NmcA, where meropenem MICs can reach 4-32 mg/L or higher 7
• Isolates with meropenem MIC ≥2 mg/L should be considered resistant for clinical purposes 8

Resistance Mechanisms to Monitor

The FDA label identifies four key resistance mechanisms 1:

1. Decreased outer membrane permeability (reduced porin production)
2. Reduced PBP affinity
3. Increased efflux pump expression
4. Production of carbapenemases or metallo-β-lactamases

AmpC Considerations for E. cloacae

• E. cloacae possesses inducible chromosomal AmpC β-lactamases that can be selected during therapy 9
• While meropenem is generally stable to AmpC, exposure can select for AmpC alterations and other resistance mechanisms 9
• Serial passage studies show meropenem can select for 16- to 128-fold MIC increases in E. cloacae 9

Clinical Decision Algorithm

Use meropenem for E. coli and E. cloacae when:

1. Susceptibility testing confirms meropenem MIC in susceptible range
2. No carbapenemase genes detected
3. Severe infection requiring broad-spectrum coverage
4. Patient has failed or cannot tolerate narrower-spectrum agents

Avoid or reconsider meropenem when:

1. Meropenem MIC ≥2 mg/L (defines carbapenem resistance) 8
2. Known carbapenemase production (KPC, NDM, IMP, etc.)
3. Prior carbapenem exposure with clinical failure
4. Epidemiologic risk factors for CRE (healthcare-associated infection, prior carbapenem use, endemic areas)

Alternative Strategies for Resistant Isolates

For carbapenem-resistant E. coli or E. cloacae, guidelines recommend 6:

• Meropenem-vaborbactam or ceftazidime-avibactam for KPC-producing strains
• Cefiderocol for metallo-β-lactamase producers
• Combination therapy (aztreonam + ceftazidime-avibactam) for metallo-β-lactamase-producing strains

Research confirms that meropenem-vaborbactam achieves bactericidal activity against KPC-producing E. cloacae and E. coli with MICs up to 8-16 mg/L 4.

Bottom line: Meropenem provides excellent coverage for susceptible E. coli and E. cloacae, but always verify susceptibility testing and assess for carbapenem resistance risk factors before use.